May. 13 at 5:46 PM
$BMEA $MLTX are both priced like broken or half-credited stories, but their next datasets will force the market to re-rate them as platform companies overnight. For BMEA, credible early weight-loss from oral GLP-1 candidate BMF-650 would move it out of diabetes optionality and into the hottest obesity trade in biotech, while Icovamenib’s longer-dosing programs keeps the beta-cell regeneration story alive.
For MLTX, 52-week VELA durability, adolescent HS confirmation in VELA-TEEN, and a clean IZAR-1 PsA win will turn Sonelokimab from a disputed HS asset into a multi-indication IL-17A/F franchise with BLA visibility, scarcity value, and obvious strategic appeal to immunology buyers.
In both cases, the setup is explosive because the market is not paying for clean, compounding data; it is paying for skepticism — and when skepticism has to cover, triples happen fast.
Know what you own.
